Disclaimer: CME certification for these activities has expired. All information is pertinent to the timeframe in which it was released.
Best Practices in Podiatry: Improving Your Screening and Management Strategies for Diabetic Peripheral Neuropathy
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Podiatrists, endocrinologists, diabetologists, and primary care physicians.
Credit Designation Statement
The Johns Hopkins School of Medicine designates this educational activity for a maximum of 2.0 Category 1 credit toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
The estimated time to complete this educational activity: 2 hours.
Release date: October 10th, 2005. Expiration date: October 10th, 2007.
Internet CME Policy
The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. The Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based program. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME program. CME collects only the information necessary to provide you with the services that you request.
Supported by an educational grant from Eli Lilly and Company
Full Disclosure Policy Affecting CME Activities:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:
Christopher Saudek, MD
Diabetologist, Johns Hopkins University Medical Center
Director, Johns Hopkins Diabetes Center
Past President, American Diabetes Association
• Dr Saudek reports no financial interest or relationships with the industries whose products or services are discussed in or pertain to the content of this educational activity.
Andrew J. M. Boulton, MD, DSc(hon), FRCP
Professor of Medicine
University of Manchester
Manchester, United Kingdom
University of Miami
• Dr Boulton reports to be a consultant for Eli Lilly and Company and Pfizer, Inc, and to have received honorarium from Eli Lilly and Company and Pfizer, Inc.
David G. Armstrong, DPM, PhD
Professor of Surgery
Chair of Research and Assistant Dean
Dr. William M. Scholl College of Podiatric Medicine at Rosalind Franklin University of Medicine
Director, Center for Lower Extremity
Ambulatory Research (CLEAR)
Rosalind Franklin University
• Dr Armstrong reports to be a consultant to Xilas Medical, Incorportated.
Lee J. Sanders, DPM
Chief, Podiatry Service
VA Medical Center
• Dr Sanders reports serving on the advisory panel for Eli Lilly and Company.
Off Label Product Discussion
Dr Boulton has indicated that his presentation includes information on off-label products (tricyclic drugs and anti-epileptics).
Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.
This educational program has been presented at the symposium titled “Best Practices in Podiatry: Improving Your Screening and Management Strategies for Diabetic Peripheral Neuropathy” held on August 6, 2005, at the Annual Meeting of the American Podiatrist Medical Association (APMA).
Diabetes has reached epidemic proportions in the U.S. and the world; the World Heath Organization (WHO) estimates that there are currently 150 million people with diabetes. Diabetic complications are a significant threat to patient health: as many as 37% of patients will develop metabolic, macrovascular or microvascular complications. Diabetic Peripheral Neuropathy, a diabetic microvascular complication, is an extremely painful and sometimes debilitating condition that often leads to lower extremity ulceration.
Health care professionals have a pivotal role in the prevention and early diagnosis of DNP. Unfortunately, DNP is often underdiagnosed and infected ulcers result in amputation of digits or limbs, which has a devastating impact on patient quality of life. Signs and symptoms of DNP can be detected early through physical and neurological exams (i.e. tuning fork or monofilament test). Healthcare professionals are urged to pay close attention to subtle DNP signs and symptoms, and to conduct thorough screening and diagnostic tests. It is important to educate healthcare professionals on proper management of PDN and the potential role of emerging treatment and management strategies.
These presentations will review diabetic peripheral neuropathy (DPN) and its treatment. The webcast is intended for healthcare professionals who desire a better understanding of current management and treatment strategies. This program is designed to review the impact of DPN and focus on the current and emerging clinical strategies for optimizing patient outcomes. This webcast will be followed up with a CME test.